These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1349 related items for PubMed ID: 28588093

  • 1. Implantable Cardioverter-Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications.
    Orgeron GM, James CA, Te Riele A, Tichnell C, Murray B, Bhonsale A, Kamel IR, Zimmerman SL, Judge DP, Crosson J, Tandri H, Calkins H.
    J Am Heart Assoc; 2017 Jun 06; 6(6):. PubMed ID: 28588093
    [Abstract] [Full Text] [Related]

  • 2. Long-Term Clinical Outcome of Arrhythmogenic Right Ventricular Cardiomyopathy in Individuals With a p.S358L Mutation in TMEM43 Following Implantable Cardioverter Defibrillator Therapy.
    Hodgkinson KA, Howes AJ, Boland P, Shen XS, Stuckless S, Young TL, Curtis F, Collier A, Parfrey PS, Connors SP.
    Circ Arrhythm Electrophysiol; 2016 Mar 06; 9(3):. PubMed ID: 26966288
    [Abstract] [Full Text] [Related]

  • 3. Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia.
    Corrado D, Calkins H, Link MS, Leoni L, Favale S, Bevilacqua M, Basso C, Ward D, Boriani G, Ricci R, Piccini JP, Dalal D, Santini M, Buja G, Iliceto S, Estes NA, Wichter T, McKenna WJ, Thiene G, Marcus FI.
    Circulation; 2010 Sep 21; 122(12):1144-52. PubMed ID: 20823389
    [Abstract] [Full Text] [Related]

  • 4. Long-term follow-up in patients with arrhythmogenic right ventricular cardiomyopathy.
    Li CH, Lin YJ, Huang JL, Wu TJ, Cheng CC, Lin WS, Tuan TC, Chang SL, Lo LW, Hu YF, Chao TF, Chung FP, Tsai CF, Tsao HM, Chen SA.
    J Cardiovasc Electrophysiol; 2012 Jul 21; 23(7):750-6. PubMed ID: 22353378
    [Abstract] [Full Text] [Related]

  • 5. Implantable cardioverter defibrillators in arrhythmogenic right ventricular dysplasia/cardiomyopathy: patient outcomes, incidence of appropriate and inappropriate interventions, and complications.
    Schinkel AF.
    Circ Arrhythm Electrophysiol; 2013 Jun 21; 6(3):562-8. PubMed ID: 23673907
    [Abstract] [Full Text] [Related]

  • 6. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention.
    Bhonsale A, James CA, Tichnell C, Murray B, Gagarin D, Philips B, Dalal D, Tedford R, Russell SD, Abraham T, Tandri H, Judge DP, Calkins H.
    J Am Coll Cardiol; 2011 Sep 27; 58(14):1485-96. PubMed ID: 21939834
    [Abstract] [Full Text] [Related]

  • 7. Prognostic value of endocardial voltage mapping in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia.
    Migliore F, Zorzi A, Silvano M, Bevilacqua M, Leoni L, Marra MP, Elmaghawry M, Brugnaro L, Dal Lin C, Bauce B, Rigato I, Tarantini G, Basso C, Buja G, Thiene G, Iliceto S, Corrado D.
    Circ Arrhythm Electrophysiol; 2013 Feb 27; 6(1):167-76. PubMed ID: 23392584
    [Abstract] [Full Text] [Related]

  • 8. Lifelong arrhythmic risk stratification in arrhythmogenic right ventricular cardiomyopathy: distribution of events and impact of periodical reassessment.
    Cappelletto C, Stolfo D, De Luca A, Pinamonti B, Barbati G, Pivetta A, Gobbo M, Brun F, Merlo M, Sinagra G.
    Europace; 2018 Jun 01; 20(FI1):f20-f29. PubMed ID: 28633348
    [Abstract] [Full Text] [Related]

  • 9. Incidence of and predictors for appropriate implantable cardioverter-defibrillator therapy in patients with a secondary preventive implantable cardioverter-defibrillator indication.
    Schaer B, Kühne M, Reichlin T, Osswald S, Sticherling C.
    Europace; 2016 Feb 01; 18(2):227-31. PubMed ID: 26063686
    [Abstract] [Full Text] [Related]

  • 10. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia.
    Corrado D, Leoni L, Link MS, Della Bella P, Gaita F, Curnis A, Salerno JU, Igidbashian D, Raviele A, Disertori M, Zanotto G, Verlato R, Vergara G, Delise P, Turrini P, Basso C, Naccarella F, Maddalena F, Estes NA, Buja G, Thiene G.
    Circulation; 2003 Dec 23; 108(25):3084-91. PubMed ID: 14638546
    [Abstract] [Full Text] [Related]

  • 11. The ICD for primary prevention in patients with inherited cardiac diseases: indications, use, and outcome: a comparison with secondary prevention.
    Olde Nordkamp LR, Wilde AA, Tijssen JG, Knops RE, van Dessel PF, de Groot JR.
    Circ Arrhythm Electrophysiol; 2013 Feb 23; 6(1):91-100. PubMed ID: 23275262
    [Abstract] [Full Text] [Related]

  • 12. Sex Differences in Device Therapies for Ventricular Arrhythmias or Death in the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) Trial.
    Tompkins CM, Kutyifa V, Arshad A, McNitt S, Polonsky B, Wang PJ, Moss AJ, Zareba W.
    J Cardiovasc Electrophysiol; 2015 Aug 23; 26(8):862-871. PubMed ID: 25929699
    [Abstract] [Full Text] [Related]

  • 13. Ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy: clinical presentation, risk stratification and results of long-term follow-up.
    Pezawas T, Stix G, Kastner J, Schneider B, Wolzt M, Schmidinger H.
    Int J Cardiol; 2006 Mar 08; 107(3):360-8. PubMed ID: 16503259
    [Abstract] [Full Text] [Related]

  • 14. Prognostic value of QRS fragmentation in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia.
    Peters S, Truemmel M, Koehler B.
    J Cardiovasc Med (Hagerstown); 2012 May 08; 13(5):295-8. PubMed ID: 22450866
    [Abstract] [Full Text] [Related]

  • 15. Sex Differences in Inappropriate ICD Device Therapies: MADIT-II and MADIT-CRT.
    Tompkins CM, McNitt S, Polonsky B, Daubert JP, Wang PJ, Moss AJ, Zareba W, Kutyifa V.
    J Cardiovasc Electrophysiol; 2017 Jan 08; 28(1):94-102. PubMed ID: 27696593
    [Abstract] [Full Text] [Related]

  • 16. Risk Stratification in Arrhythmogenic Right Ventricular Cardiomyopathy.
    Calkins H, Corrado D, Marcus F.
    Circulation; 2017 Nov 21; 136(21):2068-2082. PubMed ID: 29158215
    [Abstract] [Full Text] [Related]

  • 17. Arrhythmic outcome of arrhythmogenic right ventricular cardiomyopathy patients without implantable defibrillators.
    Wang W, Cadrin-Tourigny J, Bhonsale A, Tichnell C, Murray B, Monfredi O, Chrispin J, Crosson J, Tandri H, James CA, Calkins H.
    J Cardiovasc Electrophysiol; 2018 Oct 21; 29(10):1396-1402. PubMed ID: 29894017
    [Abstract] [Full Text] [Related]

  • 18. Performance of the 2015 International Task Force Consensus Statement Risk Stratification Algorithm for Implantable Cardioverter-Defibrillator Placement in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy.
    Orgeron GM, Te Riele A, Tichnell C, Wang W, Murray B, Bhonsale A, Judge DP, Kamel IR, Zimmerman SL, Tandri H, Calkins H, James CA.
    Circ Arrhythm Electrophysiol; 2018 Feb 21; 11(2):e005593. PubMed ID: 29453325
    [Abstract] [Full Text] [Related]

  • 19. Predictors of appropriate implantable defibrillator therapies in patients with arrhythmogenic right ventricular dysplasia.
    Piccini JP, Dalal D, Roguin A, Bomma C, Cheng A, Prakasa K, Dong J, Tichnell C, James C, Russell S, Crosson J, Berger RD, Marine JE, Tomaselli G, Calkins H.
    Heart Rhythm; 2005 Nov 21; 2(11):1188-94. PubMed ID: 16253908
    [Abstract] [Full Text] [Related]

  • 20. Implantable cardiac defibrillator events in patients with arrhythmogenic right ventricular cardiomyopathy.
    Woźniak O, Borowiec K, Konka M, Cicha-Mikołajczyk A, Przybylski A, Szumowski Ł, Hoffman P, Poślednik K, Biernacka EK.
    Heart; 2022 Jan 21; 108(1):22-28. PubMed ID: 33674353
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 68.